Prestige Consumer Healthcare (NYSE:PBH) Upgraded at StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

Other research analysts also recently issued reports about the company. Jefferies Financial Group reaffirmed a “hold” rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson reiterated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research report on Monday, December 9th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average price target of $85.25.

Prestige Consumer Healthcare Stock Up 0.9 %

Shares of PBH stock opened at $74.45 on Tuesday. The company has a market capitalization of $3.68 billion, a price-to-earnings ratio of 18.11, a PEG ratio of 2.32 and a beta of 0.51. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The stock’s 50 day simple moving average is $80.53 and its 200 day simple moving average is $74.17. Prestige Consumer Healthcare has a twelve month low of $58.22 and a twelve month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. The business had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. Prestige Consumer Healthcare’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.07 EPS. As a group, research analysts predict that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insider Transactions at Prestige Consumer Healthcare

In related news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now directly owns 20,058 shares in the company, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock valued at $3,187,300 in the last three months. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently made changes to their positions in the company. Nordea Investment Management AB increased its holdings in shares of Prestige Consumer Healthcare by 3.4% in the fourth quarter. Nordea Investment Management AB now owns 90,693 shares of the company’s stock worth $7,066,000 after acquiring an additional 2,985 shares in the last quarter. GAMMA Investing LLC lifted its stake in Prestige Consumer Healthcare by 18.9% in the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock valued at $108,000 after acquiring an additional 220 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Prestige Consumer Healthcare by 3.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock worth $19,630,000 after acquiring an additional 8,533 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Prestige Consumer Healthcare by 4.3% during the 3rd quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock worth $1,513,000 after acquiring an additional 894 shares in the last quarter. Finally, Sanctuary Advisors LLC raised its holdings in shares of Prestige Consumer Healthcare by 11.0% in the third quarter. Sanctuary Advisors LLC now owns 17,248 shares of the company’s stock valued at $1,244,000 after purchasing an additional 1,715 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.